WaveMan
WaveMan · Company
IAM · Iambic Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IAM Iambic Therapeutics (IAM) Insider Trading, Ownership & Congress Trades

CIK 0001997038
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
12
Codes C/M, not in net · no price filed

What the filings say about IAM

Insiders, 180 days
+$11.5M net bought
1 buyer

Iambic Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Iambic Therapeutics, Inc. insiders bought a net $11.5M of stock across 1 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Rachlin Evan Lockwood
Director
BUY
2026-10-19 SECtraded 2026-10-16
718,750
$11.5M
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 27.8% of the 2,588,248 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Director Rachlin Evan Lockwood bought about $11.5M of IAM on Oct 16, 2026, the largest insider purchase at the company on our record.
1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$11.5M over 180 days
+$11.5M over 90 days
more than 83% of its sector
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Oct 19Director Rachlin Evan Lockwood bought $11.5M (Oct 16)

Watch IAM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns IAM: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in IAM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IAM planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $11.5M bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener

IAM Stock Sonar score 1/7 axes

Find similar shapesCompare
Insider conviction
77
Inputs
  • Net Form 4 buying (codes P and S), 180d$11.5M · 98 pct, universe of 3,403
  • Insider buyers, 180d1 · 56 pct, universe of 3,445
6 not measured: Profitability, Financial health, Growth, Institutional and government, Risk and compliance, US patents
  • Profitability needs 2 of 4 inputs, 0 present: not filed
  • Financial health needs 1 of 2 inputs, 0 present: not filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • Risk and compliance needs 1 of 4 inputs, 0 present: needs two 10-Ks with a Risk Factors section (not 20-F filers or stubs); no short interest or no free float on file; revenue under $50M or not filed, so a count cannot be scaled to size
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

1 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IAM filings, in plain words

Are Iambic Therapeutics insiders buying or selling IAM?

In the 180 days to 2026-10-28, Iambic Therapeutics insiders were net buyers, a net $11.5M across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Iambic Therapeutics insiders were net buyers of IAM, a net $11.5M across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies